[{"orgOrder":0,"company":"Fusion Pharma","sponsor":"BWX Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Expanded Collaboration","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Fusion Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fusion Pharma \/ Fusion Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"225-Ac FPI-2068","moa":"Alpha-radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2024","type":"Licensing Agreement","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ Fusion Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"RadioMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ Fusion Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"FPI-2265","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"FPI-2265","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"FPI-2265","moa":"Alpha-wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"225-Ac FPI-1966","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Financing","leadProduct":"111-In FPI-1547","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Oxford Finance","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Oxford Finance"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Niowave","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Collaboration","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Fusion Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pharma \/ Fusion Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"BWX Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2023","type":"Agreement","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ BWX Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ BWX Technologies"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"225-Ac","moa":"||Neurotensin type-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Fusion Pharma","amount2":0.57999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.57999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Fusion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Fusion Pharma \/ Fusion Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FPI-2058","moa":"||Neurotensin type-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"Neurotensin type-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Ipsen"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"225-Ac FPI-2059","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FPI-2053","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Pepscan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Pepscan","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pharma \/ Pepscan"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pharma \/ AstraZeneca"}]
Find Clinical Drug Pipeline Developments & Deals by Fusion Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
